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De Novo Pathogenic SCN8A Mutation Identified by
Whole-Genome Sequencing of a Family Quartet Affected
by Infantile Epileptic Encephalopathy and SUDEP
Krishna R. Veeramah,1 Janelle E. O’Brien,4 Miriam H. Meisler,4 Xiaoyang Cheng,5
Sulayman D. Dib-Hajj,5 Stephen G. Waxman,5 Dinesh Talwar,6,7,9 Santhosh Girirajan,10
Evan E. Eichler,10 Linda L. Restifo,2,7,8 Robert P. Erickson,3,6 and Michael F. Hammer1,*
Individuals with severe, sporadic disorders of infantile onset represent an important class of disease for which discovery of the under-
lying genetic architecture is not amenable to traditional genetic analysis. Full-genome sequencing of affected individuals and their
parents provides a powerful alternative strategy for gene discovery. We performed whole-genome sequencing (WGS) on a family quartet
containing an affected proband and her unaffected parents and sibling. The 15-year-old female proband had a severe epileptic enceph-
alopathy consisting of early-onset seizures, features of autism, intellectual disability, ataxia, and sudden unexplained death in epilepsy.
We discovered a de novo heterozygous missense mutation (c.5302A>G [p.Asn1768Asp]) in the voltage-gated sodium-channel gene
SCN8A in the proband. This mutation alters an evolutionarily conserved residue in Nav1.6, one of the most abundant sodium channels
in the brain. Analysis of the biophysical properties of the mutant channel demonstrated a dramatic increase in persistent sodium
current, incomplete channel inactivation, and a depolarizing shift in the voltage dependence of steady-state fast inactivation.
Current-clamp analysis in hippocampal neurons transfected with p.Asn1768Asp channels revealed increased spontaneous firing, parox-
ysmal-depolarizing-shift-like complexes, and an increased firing frequency, consistent with a dominant gain-of-function phenotype in
the heterozygous proband. This work identifies SCN8A as the fifth sodium-channel gene to be mutated in epilepsy and demonstrates the
value of WGS for the identification of pathogenic mutations causing severe, sporadic neurological disorders.Massively-parallel-sequencing technologies are revolu-
tionizing the process of discovering genetic variants that
cause disease.1 Neurodevelopmental disorders such as
epilepsy, autism spectrum disorders (ASDs), intellectual
disability (ID), and schizophrenia represent a considerable
challenge for molecular genetic analysis because of marked
genetic heterogeneity, environmental effects on the
severity of symptoms, and the frequent co-occurrence of
seizures, autism, and cognitive phenotypes. Studies of
copy-number variation (CNV) have demonstrated the
contribution of de novo variants in these disorders.2,3
However, CNVs only appear to contribute to between
10% and 25% of affected cases.4 It is hypothesized that
rare or novel point mutations might contribute to many
of the remaining cases under the CD/MRV (common
disease/multiple rare variant) model.5 When the observed
phenotype is particularly severe and there is no prior
family history of the disorder, it is reasonable to consider
a disease model that involves a dominant de novo muta-
tion. Support for this model comes from studies of
epileptic encephalopathies, in which de novo mutations
of the sodium-channel gene SCN1A (MIM 182389) are a
major cause of Dravet Syndrome (MIM 607208),6 whereas
de novo mutations in STXBP1 (MIM 602926) and ARX
(MIM 300382) have been found in a number of individuals
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to be quickly removed by strong purifying selection
(because affected individuals rarely reproduce) and hence
would be extremely rare or unique in the population.
Although the human mutation rate is on the order of
1 3 10-8 to 2 3 108 per site per generation,8,9 thousands
of genes are potentially involved in neurodevelopment,10
suggesting that the number of de novo pathogenic muta-
tions could be substantial. Thus, although each individual
is expected to have only ~1 de novo mutation per
exome,11 a model of rare mutations across many genes
might explain why severe neurological disorders are rela-
tively common.12
Whole-exome sequencing of parent-offspring trios offers
a cost-effective method for screening coding regions for
mutations and has been successful in identifying candi-
date de novo variants in sporadic cases of ID,12 ASDs,13
and schizophrenia.14 However, the limitations of current
exome capture and sequencing methodologies include
incomplete or variable coverage of exons and the inability
to infer ploidy across the genome or survey regulatory vari-
ation. Whole-genome sequencing (WGS) studies are not
limited by these aspects, and when they are implemented
in a quartet framework, they have many attractive analyt-
ical advantages. For example, it is possible to precisely infer
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events,9,15 which can substantially improve the detection
and correction of sequencing errors.
In this study, we apply WGS to a family quartet affected
by a sporadic case of severe epileptic encephalopathy.
Informed consent was obtained from the family quartet,
and the study was approved by the University of Arizona
institutional review board. The female proband presented
at 6 months of age with unexplained refractory epilepsy
consisting of early-onset brief (2–10 s) generalized seizures.
When she was 4 years old, the seizure phenotype changed
to epileptic spasms. In addition to early- and later-onset
epilepsy, she manifested intellectual disability, develop-
mental delay, hypotonia, and difficulties with coordina-
tion and balance. The proband was able to walk indepen-
dently just before she turned 3 years old and started to
use 5- to 6-word phrases before the age of 4. With the onset
of epileptic spasms, her speech and language skills began
to regress over the course of 1–2 years, causing her to occa-
sionally use single words only. These language and
communication problems, in combination with regression
in social interaction and the development of obsessive-
compulsive and repetitive behaviors, led to the classifica-
tion of autism when she was 5 years old.
When the proband was 6 months old, initial electroen-
cephalograms (EEGs) showed bifrontal spikes and brief
bursts of frontocentrally predominant generalized spike-
wave activity lasting for a few seconds at a time. Some of
the bursts were associated with clinical seizures. Initial
seizures showed no association with fever or illness and
occurred very frequently up to 40–50 times per day. Subse-
quent EEGs after the proband turned 5 years old showed
diffuse slowing, multifocal spikes, bifrontal and frontally
predominant generalized spikes, and runs of frontally
predominant slow spike-wave discharges. Several brain
magnetic resonance imaging (MRI) scans performed when
shewas between6months and15 years of agewere normal,
and a PETscan failed to show any focal abnormalities. At 15
years of age, the proband died from sudden unexplained
death in epilepsy (SUDEP). An autopsy showed pulmonary
edema and only mild temporal-lobe subpial gliosis.
The proband was the first-born female child of two
phenotypically unaffected parents. Her male sibling
showed neither evidence of epilepsy nor any major cogni-
tive or motor deficits. Given the severity of the disorder
and a negative family history, we hypothesized the
involvement of a de novo mutation. To detect rare CNVs,
we performed array-based comparative genomic hybridiza-
tion (CGH) experiments.We utilized a custom 2x400K Agi-
lent microarray targeted to genomic hotspot regions
flanked by segmental duplications or Alu repeats, and we
used median probe spacing of 500 bp and probe spacing
of 14 kb in the genomic backbone. After quality-control
filtering and manual curation, we identified 93 CNV calls
(Table S1, available online). To identify rare variants of
pathogenic significance, we compared the CNV pattern
to the global CNV map developed from 8,329 controls16
and 377 additional controls analyzed on the samemicroar-The Ameray platform. Allowing for a frequency of <1% in the
general population in regions with sufficient coverage
(>10 probes), we did not find any novel pathogenic
CNVs in our proband or any that were previously associ-
ated with known genomic disorders.4
We therefore carried out WGS to look for candidate
point mutations or small insertions or deletions. WGS
was performed for the quartet by Complete Genomics
(CG). CG performs a massively parallel short-read
sequence-by-ligation methodology.17 Details of library
generation, read-mapping to the NCBI reference genome
(Build 37, RefSeq Accession numbers CM000663–
CM000686), local de novo assembly, and variant-calling
protocols have been previously described.9,17 Mean unique
sequence coverage ranged from 573 to 773, and 96%–
97% of the genome was considered fully called across the
quartet. A nucleotide position is determined to be fully
called if it meets a minimum required confidence-score
threshold (20 dB for homozygotes and 40 dB for heterozy-
gotes), which is calculated by taking into account read
depth, base-call quality values, and mapping probabilities.
All variants were annotated with ANNOVAR18 on the basis
of the UCSC Known Genes Hg19 database, which covers
84,177,555 bp of coding sequence. From the reference
sequence, we identified 31,931 variants within exons or
at splice-site boundaries on all chromosomes. There were
13,395 potentially function-altering variants on auto-
somes within the quartet.
To increase variant call quality by using Mendelian
inheritance rules and information inherent in the quartet,
we applied a hidden Markov model (HMM)9 to infer the
position of recombination events that demarcate inheri-
tance state (IS) blocks between the two siblings; this model
has been shown to identify ~70% of expected CG-gener-
ated sequencing errors. Among the potentially functional
variants, we were able to identify 205 errors on the basis
of IS consistency analysis, and we were able to unambigu-
ously recover the complete quartet genotype of 58%
(1,229/2,103) of the variants that contained missing data.
For the 11,292 variants fully called within the quartet, 34
violated the Mendelian inheritance rules and would be
consistent with a de novo mutation within the proband
(i.e., the mutation is present in the proband but not in
either parent or the sibling). Ten of these variants were dis-
carded because they were found in the 1,000 Genome
Project May 2011 release or the 69 CG public genomes,
or they were mapped within (1) error-prone regions
(defined as containing at least 5 Mendelian inheritance
errors and no more than 1,000 bp separating any two
errors), (2) known segmental duplications (Database of
Genomic Variants), (3) a repeat sequence (UCSC-defined
tracks), (4) suspicious genomic blocks identified by the
HMM IS block analysis, or (5) sites that differed signifi-
cantly in coverage from the genome-wide average. Sanger
sequencing demonstrated that 23 of the remaining 24
candidates were false positives, leaving a single, true de
novo variant in the proband.rican Journal of Human Genetics 90, 502–510, March 9, 2012 503
Figure 1. The De Novo Proband Substi-
tution p.Asn1768Asp in Sodium-Channel
SCN8A
The altered amino acid residue is located at
the cytoplasmic end of transmembrane
segment 6 in domain 4 of the channel
(for simplicity of display, we use 1-letter
amino acid codes). Residue 1768 is evolu-
tionarily conserved in mammalian and
invertebrate sodium channels, as indicated
by the examples shown on the right. The
polar asparagine residue is altered to the
charged residue aspartate in our proband.
A substitution in the corresponding
residue of SCN1A, Asn1788Lys, was identified as a de novo mutation in an individual with Dravet syndrome, another early-onset
epileptic encephalopathy.22 The following abbreviations are used: h, human; a, anole lizard; f, fish (Fugu); Dm, Drosophila melanogaster;
para, fly voltage-gated sodium channel (encoded by paralytic); hSCN5A, human cardiac sodium channel; hSCN1A, human neuronal
sodium channel; N, Asn; D, Asp; and K, Lys. Dots represent amino acid identity.To identify potential cis-acting regulatory variants in the
whole-genome sequence, we also evaluated 44,851 vari-
ants within the 50 UTR or within 1 kb upstream of the tran-
scription start site. Of these, 80 qualified as potential de
novo variants in the proband. After applying the same
filtering approach as above, we identified 23 putative de
novo variants; however, none of these was validated as a
true variant after Sanger sequencing. There were no de
novo candidates (including within the 50 UTR or 1 kb
upstream of the transcription start site) on the proband’s
X chromosomes.
The single validated de novo variant was an A>G transi-
tion at nucleotide position 5302 (c.5302A>G [NCBI
ss#477075913]) in the coding sequence of SCN8A
(NM_014191.2, MIM 600702) and resulted in an aspara-
gine (Asn) to aspartate (Asp) substitution at amino acid
1768 (p.Asn1768Asp). SCN8A is one of nine members of
the gene family encoding the voltage-gated sodium-
channel pore-forming alpha subunits.19 The SCN8A-en-
coded channel, Nav1.6, is composed of four homologous
domains, D1 to D4, each containing six transmembrane
segments. The subcellular localization of Nav1.6 includes
concentration at the axon initial segment and nodes of
Ranvier, and it is widely expressed in the CNS, where it
regulates firing patterns of excitatory and inhibitory
neurons.20 The mutated residue is located in the final
transmembrane segment adjacent to the C-terminal cyto-
plasmic domain of the channel (Figure 1). Asn1768 is
invariant in vertebrate and invertebrate sodium channels,
as shown for representative examples in Figure 1. The
substitution p.Asn1768Asp is predicted to be highly delete-
rious by Polyphen-2 analysis21 (HumDiv score ¼ 0.992;
HumVar score ¼ 0.990). Interestingly, an individual with
another form of epileptic encephalopathy (Dravet
syndrome) carries a de novo mutation in the correspond-
ing residue of the related sodium-channel gene SCN1A,22
although the actual functional consequence of this variant
has not yet been assessed.
To evaluate the functional consequences of the de novo
SCN8A mutation, we introduced the c.5302A>G nucleo-
tide mutation into the tetrodotoxin (TTX)-resistant deriva-504 The American Journal of Human Genetics 90, 502–510, March 9tive of the Nav1.6 cDNA clone, Nav1.6R.
23,24 To confirm
the absence of additional mutations, we sequenced the
entire 6 kb open reading frame prior to functional testing
by transfection into the dorsal root ganglion (DRG)
neuron-derived cell line ND7/23,25 as previously
described.26 In the presence of 300 nM TTX, endogenous
sodium currents are blocked, and currents derived from
the transfected Nav1.6R clones can be studied in isola-
tion.26 Forty eight hours after transfection, cells with
robust green fluorescence were selected for recording.
Representative families of traces of Naþ currents from
voltage-clamp recordings are shown in Figure 2A. The
persistent currents that are detected 100 ms after the onset
of step depolarization and normalized to peak transient
current increased from an average of 1.8% for cells trans-
fected with the wild-type (WT) channel to 13% for cells
transfected with the mutant channel (Figure 2A insets
and Table 1). Despite a 56% reduction in peak-current
density for cells transfected with the mutant channel,
the absolute values of the persistent current (61 5 6 pA
[n ¼ 11] for WT; and 353 5 51 pA [n ¼ 11] for
p.Asn1768Asp) and persistent-current density (2.02 5
0.20 pA/pF [n ¼ 11] for WT; and 10.51 5 1.57 pA/pF
[n ¼ 11] for p.Asn1768Asp) were more than five times
larger for the mutant channels. The voltage dependence
of the persistent current is shown in Figure 2B, and it is
greatest at þ15 mV. The p.Asn1768Asp substitution also
causes a 13 mV depolarizing shift in the voltage depen-
dence of steady-state fast inactivation and increases the
noninactivating component of the current (see arrow in
Figure 2C). The development of closed-state inactivation
is slower for the mutant channels (data for 60 mV shown
in Figure 2D), and, as expected, p.Asn1768Asp channels
produce a substantially enhanced (11 times larger)
response to slow, ramp-like depolarizing stimuli
(Figure 2E). All of these changes are known to increase
neuronal excitability; it has been shown that persistent
sodium currents contribute to the generation of parox-
ysmal depolarizing shifts (PDS), a cellular response predic-
tive of recurrent seizures.27 The mutation causes a small
depolarizing shift of 4 mV in the voltage dependence of, 2012
Figure 2. Effect of the De Novo SCN8A Substitution p.Asn1768Asp on Biophysical Properties of the Channel
(A) Representative inward currents recorded from ND7/23 cells transiently transfected with Nav1.6RWTor mutant channels. Cells were
held at120mV, and a family of step depolarizations (80 toþ60mV in 5mV increments) were applied every 5 s. Insets show persistent
inward currents (normalized bymaximal transient peak currents) fromWTand p.Asn1768Asp channels at the end of a 100ms step depo-
larization to 80 mV (black) and þ20 mV (red).
(B) Voltage dependence of persistent current. The amplitude of persistent current was measured as the mean value of currents 93–98 ms
after the onset of depolarization and is presented as a percentage of the maximal transient peak current.
(C) Voltage dependence of channel activation and steady-state fast inactivation. Channel activation was analyzed as previously
described.26 Steady-state fast inactivation was assessed with a series of 100 ms step depolarizations (130 to 10 mV in 10 mV
increments) and was followed by a test pulse (10 mV) so the remaining fraction of noninactivated channels could be measured.
The p.Asn1768Asp channels do not completely inactivate, which is consistent with the large persistent current.
(D) Development of closed-state inactivation at 60 mV. Cells were held at 120 mV, and closed-state inactivation was assessed with a
prepulse set to60mVwith a duration varying from 0 to 500ms, and remaining available channels were assessed with a test pulse set to
0 mV (20 ms).
(E) Mean ramp currents generated byWT (black) and p.Asn1768Asp (red) channels. The response to a slow ramp stimulus was evaluated
with a ramp depolarization from120 toþ40mVover 800ms. The p.Asn1768Aspmutation increases the amplitude of the ramp current
(normalized by transient peak current; p.Asn1768Asp [13.65 1.9%, n ¼ 5, p < 0.05] versus WT [1.2 5 0.2%, n ¼ 7]).activation (Figure 2C) and shifts the voltage dependence
of steady-state slow inactivation by 11.6 mV (not
shown), which would reduce the proexcitatory effects.
The biophysical properties of p.Asn1768Asp channels are
summarized in Table 1. In heterozygous neurons, mutant
and WT alpha subunits would be coexpressed and act
independently. The direction and magnitude of the proex-
citatory effects of the p.Asn1768Asp substitution are con-
sistent with a dominantly expressed phenotype of
abnormal neuronal excitability. To test this prediction, we
examined the firing patterns of cultured hippocampal
neurons (dissociated from P10–P14 [postnatal days 10–14]
Sprague Dawley rats) expressing transfected mutant and
WT Scn8a cDNAs by using current-clamp recordings
(Figures 3A–3C). Spontaneous firing was detected inThe Ame3/17 (18%) neurons transfected with the WT Scn8a cDNA
and in a significantly higher percentage (10/17; 59%, p <
0.05) of neurons transfected with c.5302A>G (Figure 3B);
these latter neurons also displayed PDS-like complexes
(Figure3Aii). In response to current injection, the frequency
of action potentials was twice as high in cells expressing the
mutant channels (Figure 3C). These observations demon-
strate that expression of the mutant channel results in
a phenotype of neuronal hyperexcitability, including
increased spontaneous firing and PDS-like complexes.
Several factors support a causal role for the SCN8A
c.5302A>G mutation in the phenotype observed in the
proband: (1) SCN8A encodes a neuronal sodium channel
that is highly abundant in the brain,20,28 (2) the amino
acid substitution produces a substantial increase inrican Journal of Human Genetics 90, 502–510, March 9, 2012 505
Table 1. Biophysical Effects of the SCN8A p.Asn1768Asp Substitution
INa Density
(pA/pF)
I persistent
(% of Ipeak)
Reversal
Potential
(mV)
Activation Steady-State Fast Inactivation Slow Inactivation
V1/2,act k n V1/2,fast k A% n V1/2,slow k A% n
WT 1305
21 (20)
1.85
0.3 (11)
69.0 5
1.6
19.5 5
0.8
6.16 5
0.27
17 62.1 5
1.0
5.61 5
0.11
2.85 5
0.51
16 41.7 5
1.3
14.2 5
0.5
3.84 5
1.01
14
N1768D 57 5
7a (24)
13.1 5
0.9a (11)
71.0 5
1.5
15.3 5
0.9a
6.96 5
0.25a
14 48.7 5
0.9a
5.77 5
0.17
10.9 5
0.86a
10 53.3 5
1.5a
6.55
0.3a
2.15 5
0.69
10
Whole-cell voltage-clamp recordings were performed with an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA). The pipette solution contained
(in mM) 140 CsF, 10 NaCl, 1 EGTA, 10 Dextrose, 10 HEPES (pH 7.3) (with CsOH), and osmolarity was adjusted to 315mosmol/liter with sucrose. The extracellular
bath solution contained (in mM) 140 NaCl, 3 KCl, 20 tetraethylammonium, 1 MgCl2, 1 CaCl2, 10 HEPES, 5 CsCl, 0.1 CdCl2 (pH 7.3) (with NaOH); osmolarity was
325 mosmol/liter. 300 nM tetrodotoxin was added to the extracellular bath solution to block endogenous voltage-gated sodium currents in ND7/23.26 All record-
ings were conducted at room temperature (~22C). Currents were acquired with Clampex 9.2 5 min after establishing whole-cell configuration, sampled at 50 or
100 kHz, and filtered at 5 kHz. The following abbreviations are used: INa, voltage-gated sodium current; Ipersistent, sodium current that is resistant to fast inactivation
at the end of 100 ms step depolarization; Ipeak, the maximal transient peak sodium current; V1/2,act, the potential at which activation of sodium channels reaches
half maximal; k, the slope factor; A%, the percentage of sodium channels that are resistant to fast inactivation or slow inactivation; n, number of cells.
ap value < 0.05 compared to WT.persistent and ramp currents and results in neuronal
hyperexcitability that includes increased spontaneous
activity and PDS-like complexes, and (3) heterozygous
mutations with similar properties in other closely related
neuronal sodium channels cause epilepsy.19 This result
demonstrates the power of theWGS approach for unbiased
discovery of pathogenic mutations in neurological disor-
ders of unknown etiology. Causative variants in severe,
early-onset neurological diseases are likely to be rare and
distributed across many genes, some of which are not on
candidate-gene lists.29 This study presents the fifth
member of the voltage-gated sodium-channel gene family
to be implicated in seizure disorders; the other four are
SCN1A, SCN2A (MIM 182390), SCN3A (MIM 182391),
and SCN9A (MIM 603415).19 In addition to SCN1A and
the cardiac channel SCN5A (MIM 600163), SCN8A is the
third sodium channel to be implicated in SUDEP, which
accounts for deaths in up to 38% of people with epilep-
sies.30 In this context, it is interesting that both Scn1a
and Scn8a are expressed at a low level in cardiac myo-
cytes,31 and cardiac function is impaired in Scn8a-null
mice.32
The in vivo physiological roles of Nav1.6 have been
extensively studied in mice. The allele series of recessive
Scn8a mutations includes missense, hypomorphic, and
null alleles.26,33–35 Motor deficits are prevalent because of
the important role of Nav1.6 at nodes of Ranvier in motor
neurons. Homozygotes for partial- and complete-loss-of-
function alleles exhibit ataxic gait, tremor, dystonia,
muscle atrophy, loss of hind-limb function, and juvenile
lethality caused by loss of neurotransmitter release at the
neuromuscular junction. The single previously reported
SCN8A mutation is a premature stop codon identified in
a proband with cerebellar ataxia; the mutation cosegre-
gated with cognitive impairment but did not result in
seizures.36 Likewise, heterozygous Scn8aþ/ mice exhibit
an anxiety-like behavioral disorder but do not have spon-
taneous seizures.37 Thus, haploinsufficiency of SCN8A
does not cause epilepsy in humans or mice. However,
spike-wave discharge patterns are seen in certain Scn8a506 The American Journal of Human Genetics 90, 502–510, March 9heterozygotes,38 and heterozygosity for an Scn8a-null
allele can suppress seizures in an Scn1aþ/ mouse model
of Dravet syndrome,39 demonstrating physiological inter-
action between these two sodium channels in determining
neuronal excitability.
The mutation in the proband is a gain-of-function allele
of SCN8A and causes a large increase in ramp and persis-
tent currents and incomplete channel inactivation.
Increased persistent current is a common characteristic of
gain-of-function SCN1A mutations in individuals with
generalized epilepsy with febrile seizures plus (GEFSþ)
and is characteristic of pathogenic mutations of SCN2A
and SCN3A.40–45 The Q54 mouse model expresses an
Scn2a mutant channel with an elevated persistent current
that causes a dominant seizure disorder.46 Notably, trans-
fection of hippocampal neurons with p.Asn1768Asp chan-
nels resulted in hyperexcitability that included increased
spontaneous activity and PDS-like complexes. The effect
of the proband’s SCN8Amutation on the persistent current
is considerably more severe than the reported examples in
other channels, which strongly supports a causal role in
the severe, dominant epileptic encephalopathy.
Mutations in SCN1A are themost common genetic cause
of inherited and sporadic epilepsy, and >700 proband
mutations, of which >80% are found in individuals with
Dravet syndrome, have been reported thus far.6,47,48 More
than 90% of the SCN1Amutations in individuals with Dra-
vet syndrome arose de novo andmore than 50% are loss-of-
functionmutations, demonstrating that, unlike for SCN8A,
haploinsufficiency for SCN1A results in seizures.19,34 Our
proband displays many features typically found in individ-
uals with Dravet syndrome; one such feature is infancy-
onset seizures that ultimately become refractory to thera-
peutic intervention and cause epileptic encephalopathy
as a result of the regression of developmental abilities.
However, consistent with a distinct genetic basis, there
are also important differences: (1) Our proband did not
manifest prolonged generalized convulsive or unilateral
febrile and afebrile seizures in the first year of life; (2) rather
than display distinct myoclonic and generalized, 2012
Figure 3. Effect of the De Novo SCN8A Substitution p.Asn1768Asp on Hippocampal Neuronal Excitability
(A) p.Asn1768Asp channels increase excitability of hippocampal neurons. (Ai) An example of spontaneous firing in a neuron transfected
with p.Asn1768Asp channels. (Aii) Representative PDS-like complexes recorded from two hippocampal pyramidal neurons transfected
with p.Asn1768Asp. The dashed lines indicate 80 mV.
(B) Percentage of neurons displaying spontaneous firing. The asterisk indicates p < 0.05.
(C) Number of action potentials (APs) evoked by a series of 1 s step depolarizating current injections (from 5 to 40 pA with a 5 pA incre-
ment). Neurons transfected with p.Asn1768Asp produce more APs than neurons transfected with WT. An asterisk indicates p < 0.05.convulsive seizures as seen in typical Dravet syndrome,
our proband had late-onset epileptic spasms characterized
by repetitive clusters of jerks with the classical EEG pattern
of spasms (i.e., high-amplitude delta wave followed by
background suppression); and (3) a period of normal devel-
opment was not seen in our proband. Delineating the clin-
ical variability within this group and distinguishing the
phenotypes of carriers of pathogenic mutations in SCN8A
and SCN1Awill require further characterization of individ-
uals with SCN8A mutations.
We also evaluated the WGS data from our quartet for
a model of inherited homozygous recessive disease. Vari-
ants with a frequency >1% in the 1,000 Genomes Project
or in the CG public genomes were excluded as potential
candidates. Seven genes fit a recessive inheritance pattern
in the proband only (Table S2). Two of these (NRP2 and
UNC13C) were cases of compound heterozygosity that
appeared functionally relevant on the basis of the Aut-
works database and biomedical literature. Both parents
were heterozygous for nonsynonymous variants in NRP2
(neuropilin 2, MIM 602070) and UNC13C (unc-13 homolog
C [C. elegans]). The inherited variants were predicted to be
deleterious by PolyPhen-2 analysis (HumDiv > 0.993) and
were extremely rare; they had frequencies <1% in the
National Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project (see Web Resources). The maternally
inherited NRP2 allele, also transmitted to the brother, is
c.1000C>T (p.Arg334Cys) (rs14144673), whereas the
paternally inherited allele is c.1282C>T (p.Arg428Trp)
(rs139711818). The maternally inherited UNC13C allele
is c.912C>G (p.Asp304Glu) (rs149448818), and the pater-
nally inherited allele is c.6587T>C (p.Val2196Ala)
(rs146433220).
NRP2 is a transmembrane receptor for class 3 semaphor-
ins, secreted proteins that are essential for guiding axon
pathfinding and sorting during central- and peripheral-
nervous-system development.49 NRP2 polymorphisms
have been associated with autism,50 and NRP2 is a candi-The Amedate gene for juvenile myoclonic epilepsy.51 Nrp2-deficient
mice display increased neuronal excitability and suscepti-
bility to chemically induced seizures.52 Loss-of-function
Nrp2 mutations in homozygous mice cause defects of
axon-tract formation, such as the misrouting, disorganiza-
tion, or loss of fiber bundles.49 Moreover, loss of Nrp2
causes increased cortical and hippocampal dendritic-spine
numbers53 and decreased numbers of hippocampal inter-
neurons and GABAergic synapses.52 The UNC13 gene
family encodes highly conserved proteins, most of which
are expressed in neurons, where they serve a crucial func-
tion in synaptic-vesicle fusion for neurotransmitter
release.54,55 Disrupting the function of any single Unc13
gene can impair neuronal function, including synaptic
plasticity56 and motor learning,57 in mouse mutants
without disrupting neuronal morphology.
It has often been suggested that the inheritance of modi-
fier loci contributes to the wide phenotypic variability of
individuals with SCN1A mutations.19 With WGS data, it
is now possible to predict the identity of specific candidate
modifier variants in individuals. In the present case, NRP2
variants could plausibly enhance seizures through
neuronal hyperexcitability and the loss of inhibitory
synapses, whereas UNC13C variants could reduce seizure
activity by inhibiting synaptic-vesicle release and thereby
increasing the threshold for synaptic transmission. Testing
the role of genetic interactions in modifying the pheno-
typic expression of SCN8A gain-of-function mutations
will require new animal models.
In summary, by performing high-coverage WGS on a
family quartet, we have identified a de novo SCN8Amuta-
tion that can account for the epileptic encephalopathy
that eventually resulted in SUDEP in the proband. Recent
whole-genome and whole-exome approaches have been
remarkably successful in identifying amino-acid-altering
de novo mutations in individuals with severe neurological
disorders. However, inmost cases to date, direct support for
causality has been lacking, and knowledge of the gene orrican Journal of Human Genetics 90, 502–510, March 9, 2012 507
protein function has allowed only predictions about the
consequences of a particular mutation.We have confirmed
the pathogenicity of our candidate SCN8A c.5302A>G
mutation through the biophysical characterization of the
channel and electrophysiological analysis in primary
neurons. Given the likely importance of rare variants with
large effects in disease etiology,5,58 such follow-up func-
tional analysis will be vital as an increasing number of de
novo or extremely rare variants are discovered through
WGS of probands and their families.Supplemental Data
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